메뉴 건너뛰기




Volumn 107, Issue 2, 2012, Pages 230-233

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: Results from the IBIS-I trial

Author keywords

breast cancer; CYP2D6 polymorphism; hot flushes; tamoxifen

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; FLUOXETINE; PAROXETINE; PLACEBO; QUINIDINE; TAMOXIFEN;

EID: 84863724665     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.278     Document Type: Article
Times cited : (18)

References (25)
  • 1
    • 79958754972 scopus 로고    scopus 로고
    • Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
    • Azoulay L, Dell'Aniello S, Huiart L, du Fort GG, Suissa S (2011) Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 126(3): 695-703
    • (2011) Breast Cancer Res Treat , vol.126 , Issue.3 , pp. 695-703
    • Azoulay, L.1    Dell'Aniello, S.2    Huiart, L.3    Du Fort, G.G.4    Suissa, S.5
  • 4
    • 68749113944 scopus 로고    scopus 로고
    • Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The 'personalised' approach?
    • Brauch H, Jordan VC (2009) Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer 45(13): 2274-2283
    • (2009) Eur J Cancer , vol.45 , Issue.13 , pp. 2274-2283
    • Brauch, H.1    Jordan, V.C.2
  • 5
    • 80052059849 scopus 로고    scopus 로고
    • First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial
    • IBIS investigators
    • Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T, IBIS investigators (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336): 817-824
    • (2002) Lancet , vol.360 , Issue.9336 , pp. 817-824
    • Cuzick, J.1    Forbes, J.2    Edwards, R.3    Baum, M.4    Cawthorn, S.5    Coates, A.6    Hamed, A.7    Howell, A.8    Powles, T.9
  • 6
    • 33847793068 scopus 로고    scopus 로고
    • Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial
    • International Breast Cancer Intervention Study I Investigators
    • Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators (2007) Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99(4): 272-282
    • (2007) J Natl Cancer Inst , vol.99 , Issue.4 , pp. 272-282
    • Cuzick, J.1    Forbes, J.F.2    Sestak, I.3    Cawthorn, S.4    Hamed, H.5    Holli, K.6    Howell, A.7
  • 7
    • 56449112123 scopus 로고    scopus 로고
    • Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial
    • ATAC Trialists' Group
    • Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists' Group (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12): 1143-1148
    • (2008) Lancet Oncol , vol.9 , Issue.12 , pp. 1143-1148
    • Cuzick, J.1    Sestak, I.2    Cella, D.3    Fallowfield, L.4
  • 8
    • 4243063941 scopus 로고    scopus 로고
    • Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
    • Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310(3): 1062-1075
    • (2004) J Pharmacol Exp Ther , vol.310 , Issue.3 , pp. 1062-1075
    • Desta, Z.1    Ward, B.A.2    Soukhova, N.V.3    Flockhart, D.A.4
  • 12
    • 76749143669 scopus 로고    scopus 로고
    • CYP2D6 polymorphisms and tamoxifen metabolism: Clinical relevance
    • Higgins M J, Stearns V (2010) CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep 12(1): 7-15
    • (2010) Curr Oncol Rep , vol.12 , Issue.1 , pp. 7-15
    • Higgins, M.J.1    Stearns, V.2
  • 14
    • 34548532227 scopus 로고    scopus 로고
    • Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer
    • Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25(25): 3837-3845
    • (2007) J Clin Oncol , vol.25 , Issue.25 , pp. 3837-3845
    • Lim, H.S.1    Ju Lee, H.2    Seok Lee, K.3    Sook Lee, E.4    Jang, I.J.5    Ro, J.6
  • 20
    • 33748440400 scopus 로고    scopus 로고
    • Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms
    • Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J (2006) Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 24(24): 3991-3996
    • (2006) J Clin Oncol , vol.24 , Issue.24 , pp. 3991-3996
    • Sestak, I.1    Kealy, R.2    Edwards, R.3    Forbes, J.4    Cuzick, J.5
  • 21
    • 1842680082 scopus 로고    scopus 로고
    • A breast cancer prediction model incorporating familial and personal risk factors
    • Tyrer J, Duffy S W, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7): 1111-1130
    • (2004) Stat Med , vol.23 , Issue.7 , pp. 1111-1130
    • Tyrer, J.1    Duffy, S.W.2    Cuzick, J.3
  • 25


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.